Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia

Nardeen Ayad, Rachael F. Grace, David J. Kuter, Hanny Al-Samkari

Blood (2022) 140 (26): 2849–2852.

https://doi.org/10.1182/blood.2022016757

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Risk of Developing Immune Thrombocytopenia and Hematologic Neoplasia in Adults with Persistent, Isolated Mild Thrombocytopenia

Nardeen Ayad, Rachael F. Grace, David J. Kuter, Hanny Al-Samkari

Blood (2022) 140 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2022-168000

Published: 2022

Journal Articles

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study (FORWARD) of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

David J. Kuter, Caroline I. Piatek, Khalil Saikali, Wolfgang Dummer

Blood (2022) 140 (Supplement 1): 2438–2439.

https://doi.org/10.1182/blood-2022-169652

Published: 2022

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J. Kuter, Hanny Al-Samkari, James B. Bussel, Marie Godar, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian C. Newland

Blood (2022) 140 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2022-167838

Published: 2022

Journal Articles

Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Hanny Al-Samkari, Caglayan Geredeli, Cagatay Arslan, Ippokratis Korantzis, Gamze Gokoz Dogu, Marina Nechaeva, Mercedes Salgado Fernandez, Beatriz Gonzalez Astorga, Valeriy Yordanov, Tudor-eliade Ciuleanu, Charles Bowers, Armando Armas, Florian Scotte, Johnny Camargo, César Muñoz, Paul Bunn, David J. Kuter, Gerald A. Soff

Blood (2022) 140 (Supplement 1): 11250–11252.

https://doi.org/10.1182/blood-2022-155931

Published: 2022

Journal Articles

Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study

David J. Kuter, Waleed Ghanima, Umer Khan, Mengyao Li, Jenny Shan, Ahmed Daak, Nichola Cooper

Blood (2022) 140 (Supplement 1): 5559–5561.

https://doi.org/10.1182/blood-2022-162426

Published: 2022

Journal Articles

Cognitive Impairment Among Patients with Chronic Immune Thrombocytopenia

David J. Kuter, Umer Khan, Paul Maruff, Chris Edgar, Jason Cromer, Gabe Stellman, Lydia King, Kathie Markowski, Ahmed Daak

Blood (2022) 140 (Supplement 1): 8422–8424.

https://doi.org/10.1182/blood-2022-156054

Published: 2022

Journal Articles

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Eun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer DiRaimo, Terry Gernsheimer, Alexandra Kruse, Craig Kessler, Caroline Kruse, Andrew D. Leavitt, Alfred I. Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D. Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B. Bussel

Blood (2022) 139 (10): 1564–1574.

https://doi.org/10.1182/blood.2021013411

Published: 2022

Includes: Supplemental data

Journal Articles

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

Blood (2021) 138 (Supplement 1): 14.

https://doi.org/10.1182/blood-2021-145128

Published: 2021

Journal Articles

Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study)

Galina Tsykunova, Pal André Holme, Hoa Thi Tuyet Tran, Tor Henrik Anderson Tvedt, Ludvig Andre Munthe, Marc Michel, Henrik Frederiksen, James B Bussel, David J. Kuter, Waleed Ghanima

Blood (2021) 138 (Supplement 1): 2088.

https://doi.org/10.1182/blood-2021-151410

Published: 2021

Journal Articles

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

Eun-Ju Lee, Marina Beltrami Moreira, Hanny Al-Samkari, Adam Cuker, Jennifer MacWhirter - DiRaimo, Terry B. Gernsheimer, Alexandra Kruse, Craig M. Kessler, Caroline Kruse, Andrew D Leavitt, Alfred Ian Lee, Howard A. Liebman, Adrian C. Newland, Ashley E. Ray, Michael D Tarantino, Jecko Thachil, David J. Kuter, Douglas B. Cines, James B Bussel

Blood (2021) 138 (Supplement 1): 586.

https://doi.org/10.1182/blood-2021-152918

Published: 2021

Journal Articles

Thrombopoietin Level Predicts Response to Treatment with Romiplostim in Chemotherapy-Induced Thrombocytopenia

Andrew B Song, Katayoon Goodarzi, Rebecca Karp Leaf, David J. Kuter, Hanny Al-Samkari

Blood (2021) 138 (Supplement 1): 584.

https://doi.org/10.1182/blood-2021-145931

Published: 2021

Journal Articles

LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia

David J. Kuter, James B Bussel, Nichola Cooper, Terry Gernsheimer, Michele P. Lambert, Howard Liebman, Michael D Tarantino, Olga Bandman, Puneet Arora, Ann Neale, Regan Burns, Mengjie Yao, Waleed Ghanima

Blood (2021) 138 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2021-144504

Published: 2021

Journal Articles

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Waleed Ghanima, Terry Gernsheimer, David J. Kuter

Blood (2021) 137 (20): 2736–2744.

https://doi.org/10.1182/blood.2021010968

Published: 2021

Journal Articles

Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19

Hanny Al-Samkari, MD, Fei Song, MD, Elizabeth M. Van Cott, MD, David J. Kuter, MD, Rachel P. Rosovsky, MD MPH

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134605

Published: 2020

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up

Alexander Röth, MD, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, MD, Bernd Jilma, Tor Henrik Anderson Tvedt, Ilene C. Weitz, Parija Patel, Xiaoyu Jiang, Caroline Reuter, Jun Su, Frank Shafer, Michelle Lee, William Hobbs, Sigbjørn Berentsen

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-138909

Published: 2020

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Adrian C. Newland, Howard A. Liebman, MD, Vickie McDonald, MD, Marc Michel, Yoshitaka Miyakawa, Wim Parys, MD, Hans De Haard, Peter Ulrichts, Marie Godar, Kristof De Beuf, Jaume Ayguasanosa, Catherine M Broome, David J. Kuter, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141161

Published: 2020

Journal Articles

Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study

Nichola Cooper, MD, Robert P. Numerof, PhD, Sandra Tong, MD, David J. Kuter, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-140469

Published: 2020

Journal Articles

Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations

Wynn Peterson, MD, Rachel Martin, MD, Brendan Carvalho, MD, Jose Carvalho, MD, Jeff Gadsden, MD, Peter A. Kouides, MD, David J. Kuter, MD, Michelle Lavin, MB, PhD FRCPath, Natalia Rydz, Eliane Shore, MDMSc FRCSC, Michelle Sholzberg, MDM, FRCPC, MSc

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-138837

Published: 2020

Journal Articles

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

David J. Kuter, MD, Merlin Efraim, MD, Jiri Mayer, MD, Vickie McDonald, MD, Robert J. Bird, FRACP,FRCP,FRCPA,MBBS,MRCP, Thomas Regenbogen, MD, Mamta Garg, MD FRCP, FRCPath, Zane Kaplan, MBBS(Hons) BMedSc(Hons) PhDFRACP FRCPA, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-134932

Published: 2020

NARROW

Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia

Long-Term Risk of Developing Immune Thrombocytopenia and Hematologic Neoplasia in Adults with Persistent, Isolated Mild Thrombocytopenia

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study (FORWARD) of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Clinical Predictors of Response to Rilzabrutinib Therapy in Patients with Immune Thrombocytopenia: Exploratory Analysis of a Phase 1/2 Study

Cognitive Impairment Among Patients with Chronic Immune Thrombocytopenia

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study)

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

Thrombopoietin Level Predicts Response to Treatment with Romiplostim in Chemotherapy-Induced Thrombocytopenia

LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia

How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment

Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up

Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study

Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only